The EPS projection of Allergan, Inc. (NYSE:AGN) for quarter ended 2016-09-30 is $3.66. Last week, the projection for EPS was $3.66 against target of $3.66, a month earlier. While 2-months ago, this projection was $3.66 versus forecast of $3.66a quarter months earlier, posting a deviation of 0%.
Allergan, Inc. (NYSE:AGN) posted that 18 days earlier, the share price was revised 0 times on upside. In addition, negative revisions were 2.
In last week, negative EPS revisions were 0 times and positive EPS revisions were 0 times. In last one-month and two month the positive revisions were 1 and 1. While in last 120 and 90 days, positive revisions were 4, and 4, correspondingly.
The per-share earnings downgrade for Allergan, Inc. (NYSE:AGN) in the preceding 30 and 120 were 0 and 2. While in 60 and 90 days were 0, and 2, in that order.
Allergan, Inc. (NYSE:AGN) EPS target was $3.66 for the quarter closed 1. It was based on 9 calls. As on 2016-05-10 the EPS was $3.04. The change was $0.05, posting a deviation of 1.67%. The price projections gave a standard deviation of 0.1.
Quarterly Sales Estimates
Allergan, Inc. (NYSE:AGN) sales prediction for the fiscal 2016 stands at $4618.166 and the median estimate is at $4660.5. Almost 3 analysts gave sales target.
Among this, the highest sales estimate is $4672 while the lowest target is $4522 showing standard deviation of 83.481%.
As many as 3 analysts have positive sales targets revision while 3 reduced sales estimates, posting a deviation of 0%.
Last month, 3 experts have positive sales number revision. Also, 3 research groups lowered the sales projections, posting a deviation of 0%.
A quarter ago, 3 hiked sales target and 3 reduced sales forecast, posting a deviation of 1.131%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...